These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38777220)

  • 1. Chelating mitochondrial iron and copper: Recipes, pitfalls and promise.
    Lamačová LJ; Trnka J
    Mitochondrion; 2024 Sep; 78():101903. PubMed ID: 38777220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and future therapy in haemochromatosis and Wilson's disease.
    Murray KF; Lam D; Kowdley KV
    Expert Opin Pharmacother; 2003 Dec; 4(12):2239-51. PubMed ID: 14640923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prochelator strategies for site-selective activation of metal chelators.
    Oliveri V; Vecchio G
    J Inorg Biochem; 2016 Sep; 162():31-43. PubMed ID: 27297691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Metabolism of iron and copper, action of chelators and therapeutic possibilities in Wilson's disease and hemochromatosis].
    PIRART J
    Pathol Biol; 1961 May; 9():1157-74. PubMed ID: 13735975
    [No Abstract]   [Full Text] [Related]  

  • 5. Metal Ions in Alzheimer's Disease: A Key Role or Not?
    Liu Y; Nguyen M; Robert A; Meunier B
    Acc Chem Res; 2019 Jul; 52(7):2026-2035. PubMed ID: 31274278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective Effect of a New 7,8-Dihydroxycoumarin-Based Fe
    Aguirre P; García-Beltrán O; Tapia V; Muñoz Y; Cassels BK; Núñez MT
    ACS Chem Neurosci; 2017 Jan; 8(1):178-185. PubMed ID: 27806193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential application of iron chelators for the treatment of neurodegenerative diseases.
    Hider RC; Roy S; Ma YM; Le Kong X; Preston J
    Metallomics; 2011 Mar; 3(3):239-49. PubMed ID: 21344071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary iron and copper deposition: diagnostics, pathogenesis and therapeutics.
    Aaseth J; Flaten TP; Andersen O
    Scand J Gastroenterol; 2007 Jun; 42(6):673-81. PubMed ID: 17505988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.
    Kontoghiorghes GJ
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synthesis and properties of mitochondrial targeted iron chelators.
    Cilibrizzi A; Pourzand C; Abbate V; Reelfs O; Versari L; Floresta G; Hider R
    Biometals; 2023 Apr; 36(2):321-337. PubMed ID: 35366134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle and other metal chelation therapeutics in Alzheimer disease.
    Liu G; Garrett MR; Men P; Zhu X; Perry G; Smith MA
    Biochim Biophys Acta; 2005 Sep; 1741(3):246-52. PubMed ID: 16051470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle and iron chelators as a potential novel Alzheimer therapy.
    Liu G; Men P; Perry G; Smith MA
    Methods Mol Biol; 2010; 610():123-44. PubMed ID: 20013176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
    Kontoghiorghes GJ; Pattichis K; Neocleous K; Kolnagou A
    Curr Med Chem; 2004 Aug; 11(16):2161-83. PubMed ID: 15279556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular iron, but not copper, plays a critical role in hydrogen peroxide-induced DNA damage.
    Barbouti A; Doulias PT; Zhu BZ; Frei B; Galaris D
    Free Radic Biol Med; 2001 Aug; 31(4):490-8. PubMed ID: 11498282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.
    Cooper GJ
    Drugs; 2011 Jul; 71(10):1281-320. PubMed ID: 21770477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Metals in Alzheimer's Disease: An Update.
    Du B; Chen K; Wang W; Lei P
    J Alzheimers Dis; 2024; 101(s1):S141-S154. PubMed ID: 39422951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of copper and iron homeostasis by metal chelators: a possible chemotherapy for Alzheimer's disease.
    Robert A; Liu Y; Nguyen M; Meunier B
    Acc Chem Res; 2015 May; 48(5):1332-9. PubMed ID: 25946460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron chelating strategies in systemic metal overload, neurodegeneration and cancer.
    Gumienna-Kontecka E; Pyrkosz-Bulska M; Szebesczyk A; Ostrowska M
    Curr Med Chem; 2014; 21(33):3741-67. PubMed ID: 25005181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chelation therapy in Wilson's disease: from D-penicillamine to the design of selective bioinspired intracellular Cu(I) chelators.
    Delangle P; Mintz E
    Dalton Trans; 2012 Jun; 41(21):6359-70. PubMed ID: 22327203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective divalent copper chelation for the treatment of diabetes mellitus.
    Cooper GJ
    Curr Med Chem; 2012; 19(17):2828-60. PubMed ID: 22455587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.